Silence Therapeutics Plc (SLN) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Silence Therapeutics Plc  (NASDAQ: SLN)


Silence Therapeutics Plc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Silence Therapeutics Plc's ROI in the second quarter of 2026?
Silence Therapeutics Plc recorded a cumulative net loss of $-60 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -46.04%.

Within the Healthcare sector 92 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3551 to 3593.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -9.67 % 63.65 % 273.26 % 896.1 % 635.73 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 94 138 115 174 206
Return On Investment (TTM) -46.04 % -47.37 % -49.95 % -35.43 % -54.89 %
SLN's Overall Ranking # 3593 # 3551 # 0 # 0 # 0
Seq. Investment Change TTM -17.8 % -10.71 % -2.6 % 26.36 % 48.92 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -60 -75 -89 -65 -79




Return On Investment SLN's Ranking
Within: No.
Industry # 25
Sector # 93
Overall # 3593

Return On Investment Statistics
High Average Low
-33.9 %
-104.58 %
-253.77 %
(Dec 31 2021)   (Dec 31 2023)







Financial Statements
Silence Therapeutics Plc's II. Quarter Investments $ 94 Millions SLN's Balance sheet
Silence Therapeutics Plc's II. Quarter Income $ -12 Millions Quarterly SLN's Income Statement
SLN's Income by Division See SLN's Income by Division


SLN Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 62 134 22 27 120
Y / Y Investment Growth -53.44 % 509.39 % -19.21 % -77.33 % -
Net Income in Millions -89 -45 -54 -50 -39
Y / Y Net Income Growth - - - - -
Annual Return On Investment -142 % -33.81 % -246.57 % -184.91 % -32.82 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SLN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SLN's Competitors
Subscribers only: Roi for Silence Therapeutics Plc's Suppliers
Subscribers only: Return On Investment for SLN's Customers

Other Ratios
SLN's Roa SLN's Inventory Turnover Ratio SLN's Growth Rates SLN's Dividend Statistics
SLN's Profitability Ratios SLN's Asset Turnover Ratio SLN's Dividend Growth
SLN's Roe SLN's Valuation Ratios SLN's Financial Strength Ratios SLN's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI


Date modified: 2026-08-31T19:03:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.